Preview Mode Links will not work in preview mode
Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show offers a glimpse into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the evolving dynamics in the medical and healthcare landscape. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations often focus on how technology is empowering providers, care facilities, pharmaceutical companies, and payers to improve patient outcomes and reduce friction across the healthcare landscape.  Popular Topics Include: Virtual and digital health Use of AI, ML, and robots for clinical and administrative purposes  Value-based healthcare  Precision and stratified medicine Next-generation immuno, cell, and gene therapies Vaccines for infectious diseases and oncology Biomarkers and diagnostics Rare diseases MedTech and medical devices Clinical trials  Population health Chronic conditions l Clinician and staff burnout Smart hospitals The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.

Jul 9, 2026

Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics, has developed a novel class of antimicrobials that operate by disrupting bacterial and fungal cell membranes, rapidly killing the microorganisms. Traditional antimicrobials work by inhibiting bacterial growth, but bacteria have evolved resistance mechanisms against...


Jul 9, 2026

Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics, has developed a novel class of antimicrobials that operate by disrupting bacterial and fungal cell membranes, rapidly killing the microorganisms. Traditional antimicrobials work by inhibiting bacterial growth, but bacteria have evolved resistance mechanisms against...


Jul 8, 2026

Harith Rajagopalan, Co-Founder and CEO of Fractyl Health, is developing innovative therapies that target the root causes of obesity and metabolic diseases to achieve durable, long-lasting patient outcomes. Their drug is designed to address post-GLP-1 rebound weight gain by treating the underlying gut damage.  Unlike...


Jul 8, 2026

Harith Rajagopalan, Co-Founder and CEO of Fractyl Health, is developing innovative therapies that target the root causes of obesity and metabolic diseases to achieve durable, long-lasting patient outcomes. Their drug is designed to address post-GLP-1 rebound weight gain by treating the underlying gut damage.  Unlike...


Jul 8, 2026

Lior Shaltiel, CEO of NurExone, is addressing the unmet needs of those with spinal cord injuries, as current therapies only treat symptoms and do not regenerate damaged nerves from accidents or disease. The NurExone technology aims to stimulate nerve growth by targeting a protein that inhibits cell proliferation. Using...